Polyglutamine diseases: The special case of ataxin-3 and Machado-Joseph disease

Progress in Neurobiology

Volumn 95, Issue 1, 2011, Pages 26-48

  Matos, Carlos A ^a   de Macedo Ribeiro, Sandra ^b   Carvalho, Ana Luísa ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Ataxin 3; DUBs; Machado Joseph disease; Polyglutamine diseases; SCA3

Indexed keywords

ATAXIN 3; CELL PROTEIN; CYTOSKELETON PROTEIN; MUTANT PROTEIN; POLYGLUTAMINE; POLYUBIQUITIN;

ATAXIA; CAG REPEAT; CELL FUNCTION; CELL SURVIVAL; CELL TRANSPORT; CLINICAL FEATURE; CYTOSKELETON; DEGENERATIVE DISEASE; DISEASE COURSE; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; MACHADO JOSEPH DISEASE; MUSCLE DEVELOPMENT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; STRESS; TRANSCRIPTION REGULATION;

ANIMALS; CELL DEATH; DISEASE MODELS, ANIMAL; HUMANS; MACHADO-JOSEPH DISEASE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PEPTIDES; PROTEIN CONFORMATION; REPRESSOR PROTEINS;

EID: 79960668226     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2011.06.007     Document Type: Review

References (193)

1. Albrecht M., Golatta M., Wullner U., Lengauer T. Structural and functional analysis of ataxin-2 and ataxin-3. Eur. J. Biochem. 2004, 271:3155-3170.
2. Alves S., Nascimento-Ferreira I., Auregan G., Hassig R., Dufour N., Brouillet E., Pedroso de Lima M.C., Hantraye P., Pereira de Almeida L., Deglon N. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 2008, 3:e3341.
3. Alves S., Nascimento-Ferreira I., Dufour N., Hassig R., Auregan G., Nobrega C., Brouillet E., Hantraye P., Pedroso de Lima M.C., Deglon N., de Almeida L.P. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?. Hum. Mol. Genet. 2010, 19:2380-2394.
4. Alves S., Regulier E., Nascimento-Ferreira I., Hassig R., Dufour N., Koeppen A., Carvalho A.L., Simoes S., de Lima M.C., Brouillet E., Gould V.C., Deglon N., de Almeida L.P. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. Hum. Mol. Genet. 2008, 17:2071-2083.
5. Antony P.M., Mantele S., Mollenkopf P., Boy J., Kehlenbach R.H., Riess O., Schmidt T. Identification and functional dissection of localization signals within ataxin-3. Neurobiol. Dis. 2009, 36:280-292.
6. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
7. Bauer P.O., Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem. 2009, 110:1737-1765.
8. Baylies M.K., Michelson A.M. Invertebrate myogenesis: looking back to the future of muscle development. Curr. Opin. Genet. Dev. 2001, 11:431-439.
9. Berke S.J., Chai Y., Marrs G.L., Wen H., Paulson H.L. Defining the role of ubiquitin-interacting motifs in the polyglutamine disease protein, ataxin-3. J. Biol. Chem. 2005, 280:32026-32034.
10. Berke S.J., Schmied F.A., Brunt E.R., Ellerby L.M., Paulson H.L. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J. Neurochem. 2004, 89:908-918.
11. Bettencourt C., Santos C., Montiel R., Costa Mdo C., Cruz-Morales P., Santos L.R., Simoes N., Kay T., Vasconcelos J., Maciel P., Lima M. Increased transcript diversity: novel splicing variants of Machado-Joseph disease gene (ATXN3). Neurogenetics 2009, 11:193-202.
12. Bevivino A.E., Loll P.J. An expanded glutamine repeat destabilizes native ataxin-3 structure and mediates formation of parallel beta -fibrils. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:11955-11960.
13. Bichelmeier U., Schmidt T., Hubener J., Boy J., Ruttiger L., Habig K., Poths S., Bonin M., Knipper M., Schmidt W.J., Wilbertz J., Wolburg H., Laccone F., Riess O. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J. Neurosci. 2007, 27:7418-7428.
14. Boeddrich A., Gaumer S., Haacke A., Tzvetkov N., Albrecht M., Evert B.O., Muller E.C., Lurz R., Breuer P., Schugardt N., Plassmann S., Xu K., Warrick J.M., Suopanki J., Wullner U., Frank R., Hartl U.F., Bonini N.M., Wanker E.E. An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis. EMBO J. 2006, 25:1547-1558.
15. Bonini N.M., La Spada A.R. Silencing polyglutamine degeneration with RNAi. Neuron 2005, 48:715-718.
16. Boy J., Schmidt T., Schumann U., Grasshoff U., Unser S., Holzmann C., Schmitt I., Karl T., Laccone F., Wolburg H., Ibrahim S., Riess O. A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats. Neurobiol. Dis. 2010, 37:284-293.
17. Boy J., Schmidt T., Wolburg H., Mack A., Nuber S., Bottcher M., Schmitt I., Holzmann C., Zimmermann F., Servadio A., Riess O. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Hum. Mol. Genet. 2009, 18:4282-4295.
18. Breuer P., Haacke A., Evert B.O., Wullner U. Nuclear aggregation of polyglutamine-expanded ataxin-3: fragments escape the cytoplasmic quality control. J. Biol. Chem. 2010, 285:6532-6537.
19. Bryson-Richardson R.J., Currie P.D. The genetics of vertebrate myogenesis. Nat. Rev. Genet. 2008, 9:632-646.
20. Burnett B., Li F., Pittman R.N. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum. Mol. Genet. 2003, 12:3195-3205.
21. Burnett B.G., Pittman R.N. The polyglutamine neurodegenerative protein ataxin 3 regulates aggresome formation. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:4330-4335.
22. Cemal C.K., Carroll C.J., Lawrence L., Lowrie M.B., Ruddle P., Al-Mahdawi S., King R.H., Pook M.A., Huxley C., Chamberlain S. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum. Mol. Genet. 2002, 11:1075-1094.
23. Chai Y., Berke S.S., Cohen R.E., Paulson H.L. Poly-ubiquitin binding by the polyglutamine disease protein ataxin-3 links its normal function to protein surveillance pathways. J. Biol. Chem. 2004, 279:3605-3611.
24. Chai Y., Koppenhafer S.L., Bonini N.M., Paulson H.L. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease. J. Neurosci. 1999, 19:10338-10347.
25. Chai Y., Koppenhafer S.L., Shoesmith S.J., Perez M.K., Paulson H.L. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum. Mol. Genet. 1999, 8:673-682.
26. Chai Y., Shao J., Miller V.M., Williams A., Paulson H.L. Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:9310-9315.
27. Chan H.Y., Warrick J.M., Andriola I., Merry D., Bonini N.M. Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Hum. Mol. Genet. 2002, 11:2895-2904.
28. Chen S., Berthelier V., Hamilton J.B., O'Nuallain B., Wetzel R. Amyloid-like features of polyglutamine aggregates and their assembly kinetics. Biochemistry 2002, 41:7391-7399.
29. Chen X., Tang T.S., Tu H., Nelson O., Pook M., Hammer R., Nukina N., Bezprozvanny I. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. J. Neurosci. 2008, 28:12713-12724.
30. Chou A.H., Chen S.Y., Yeh T.H., Weng Y.H., Wang H.L. HDAC inhibitor sodium butyrate reverses transcriptional downregulation and ameliorates ataxic symptoms in a transgenic mouse model of SCA3. Neurobiol. Dis. 2011, 41:481-488.
31. Chou A.H., Yeh T.H., Kuo Y.L., Kao Y.C., Jou M.J., Hsu C.Y., Tsai S.R., Kakizuka A., Wang H.L. Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL. Neurobiol. Dis. 2006, 21:333-345.
32. Chou A.H., Yeh T.H., Ouyang P., Chen Y.L., Chen S.Y., Wang H.L. Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol. Dis. 2008, 31:89-101.
33. Chow M.K., Ellisdon A.M., Cabrita L.D., Bottomley S.P. Polyglutamine expansion in ataxin-3 does not affect protein stability: implications for misfolding and disease. J. Biol. Chem. 2004, 279:47643-47651.
34. Chow M.K., Mackay J.P., Whisstock J.C., Scanlon M.J., Bottomley S.P. Structural and functional analysis of the Josephin domain of the polyglutamine protein ataxin-3. Biochem. Biophys. Res. Commun. 2004, 322:387-394.
35. Chow M.K., Paulson H.L., Bottomley S.P. Destabilization of a non-pathological variant of ataxin-3 results in fibrillogenesis via a partially folded intermediate: a model for misfolding in polyglutamine disease. J. Mol. Biol. 2004, 335:333-341.
36. Colomer Gould V.F., Goti D., Pearce D., Gonzalez G.A., Gao H., Bermudez de Leon M., Jenkins N.A., Copeland N.G., Ross C.A., Brown D.R. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice. Neurobiol. Dis. 2007, 27:362-369.
37. Costa M.C., Gomes-da-Silva J., Miranda C.J., Sequeiros J., Santos M.M., Maciel P. Genomic structure, promoter activity, and developmental expression of the mouse homologue of the Machado-Joseph disease (MJD) gene. Genomics 2004, 84:361-373.
38. Coutinho P., Andrade C. Autosomal dominant system degeneration in Portuguese families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. Neurology 1978, 28:703-709.
39. Cummings C.J., Zoghbi H.Y. Fourteen and counting: unraveling trinucleotide repeat diseases. Hum. Mol. Genet. 2000, 9:909-916.
40. Demuro A., Mina E., Kayed R., Milton S.C., Parker I., Glabe C.G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J. Biol. Chem. 2005, 280:17294-17300.
41. do Carmo Costa M., Bajanca F., Rodrigues A.J., Tome R.J., Corthals G., Macedo-Ribeiro S., Paulson H.L., Logarinho E., Maciel P. Ataxin-3 plays a role in mouse myogenic differentiation through regulation of integrin subunit levels. PLoS One 2010, 5:e11728.
42. Donaldson K.M., Li W., Ching K.A., Batalov S., Tsai C.C., Joazeiro C.A. Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8892-8897.
43. Dorval V., Fraser P.E. SUMO on the road to neurodegeneration. Biochim. Biophys. Acta 2007, 1773:694-706.
44. Doss-Pepe E.W., Stenroos E.S., Johnson W.G., Madura K. Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Mol. Cell. Biol. 2003, 23:6469-6483.
45. Durcan T.M., Kontogiannea M., Thorarinsdottir T., Fallon L., Williams A.J., Djarmati A., Fantaneanu T., Paulson H.L., Fon E.A. The Machado-Joseph disease-associated mutant form of ataxin-3 regulates parkin ubiquitination and stability. Hum. Mol. Genet. 2010, 20:141-154.
46. Durr A., Stevanin G., Cancel G., Duyckaerts C., Abbas N., Didierjean O., Chneiweiss H., Benomar A., Lyon-Caen O., Julien J., Serdaru M., Penet C., Agid Y., Brice A. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann. Neurol. 1996, 39:490-499.
47. Ellisdon A.M., Pearce M.C., Bottomley S.P. Mechanisms of ataxin-3 misfolding and fibril formation: kinetic analysis of a disease-associated polyglutamine protein. J. Mol. Biol. 2007, 368:595-605.
48. Ellisdon A.M., Thomas B., Bottomley S.P. The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J. Biol. Chem. 2006, 281:16888-16896.
49. Evert B.O., Araujo J., Vieira-Saecker A.M., de Vos R.A., Harendza S., Klockgether T., Wullner U. Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J. Neurosci. 2006, 26:11474-11486.
50. Evert B.O., Schelhaas J., Fleischer H., de Vos R.A., Brunt E.R., Stenzel W., Klockgether T., Wullner U. Neuronal intranuclear inclusions, dysregulation of cytokine expression and cell death in spinocerebellar ataxia type 3. Clin. Neuropathol. 2006, 25:272-281.
51. Evert B.O., Vogt I.R., Kindermann C., Ozimek L., de Vos R.A., Brunt E.R., Schmitt I., Klockgether T., Wullner U. Inflammatory genes are upregulated in expanded ataxin-3-expressing cell lines and spinocerebellar ataxia type 3 brains. J. Neurosci. 2001, 21:5389-5396.
52. Evert B.O., Vogt I.R., Vieira-Saecker A.M., Ozimek L., de Vos R.A., Brunt E.R., Klockgether T., Wullner U. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3. J. Neuropathol. Exp. Neurol. 2003, 62:1006-1018.
53. Fan M.M., Raymond L.A. N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog. Neurobiol. 2007, 81:272-293.
54. Fei E., Jia N., Zhang T., Ma X., Wang H., Liu C., Zhang W., Ding L., Nukina N., Wang G. Phosphorylation of ataxin-3 by glycogen synthase kinase 3beta at serine 256 regulates the aggregation of ataxin-3. Biochem. Biophys. Res. Commun. 2007, 357:487-492.
55. Ferrigno P., Silver P.A. Polyglutamine expansions: proteolysis, chaperones, and the dangers of promiscuity. Neuron 2000, 26:9-12.
56. Ferro A., Carvalho A.L., Teixeira-Castro A., Almeida C., Tome R.J., Cortes L., Rodrigues A.J., Logarinho E., Sequeiros J., Macedo-Ribeiro S., Maciel P. NEDD8: a new ataxin-3 interactor. Biochim. Biophys. Acta 2007, 1773:1619-1627.
57. Fiumara F., Fioriti L., Kandel E.R., Hendrickson W.A. Essential role of coiled coils for aggregation and activity of Q/N-rich prions and PolyQ proteins. Cell 2010, 143:1121-1135.
58. Fujigasaki H., Uchihara T., Koyano S., Iwabuchi K., Yagishita S., Makifuchi T., Nakamura A., Ishida K., Toru S., Hirai S., Ishikawa K., Tanabe T., Mizusawa H. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains. Exp. Neurol. 2000, 165:248-256.
59. Fujigasaki H., Uchihara T., Takahashi J., Matsushita H., Nakamura A., Koyano S., Iwabuchi K., Hirai S., Mizusawa H. Preferential recruitment of ataxin-3 independent of expanded polyglutamine: an immunohistochemical study on Marinesco bodies. J. Neurol. Neurosurg. Psychiatry 2001, 71:518-520.
60. Gales L., Cortes L., Almeida C., Melo C.V., Costa M.C., Maciel P., Clarke D.T., Damas A.M., Macedo-Ribeiro S. Towards a structural understanding of the fibrillization pathway in Machado-Joseph's disease: trapping early oligomers of non-expanded ataxin-3. J. Mol. Biol. 2005, 353:642-654.
61. Garcia-Arencibia M., Hochfeld W.E., Toh P.P., Rubinsztein D.C. Autophagy, a guardian against neurodegeneration. Semin. Cell Dev. Biol. 2010, 21:691-698.
62. Gatchel J.R., Zoghbi H.Y. Diseases of unstable repeat expansion: mechanisms and common principles. Nat. Rev. Genet. 2005, 6:743-755.
63. Goellner G.M., Rechsteiner M. Are Huntington's and polyglutamine-based ataxias proteasome storage diseases?. Int. J. Biochem. Cell Biol. 2003, 35:562-571.
64. Goti D., Katzen S.M., Mez J., Kurtis N., Kiluk J., Ben-Haiem L., Jenkins N.A., Copeland N.G., Kakizuka A., Sharp A.H., Ross C.A., Mouton P.R., Colomer V. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration. J. Neurosci. 2004, 24:10266-10279.
65. Goto J., Watanabe M., Ichikawa Y., Yee S.B., Ihara N., Endo K., Igarashi S., Takiyama Y., Gaspar C., Maciel P., Tsuji S., Rouleau G.A., Kanazawa I. Machado-Joseph disease gene products carrying different carboxyl termini. Neurosci. Res. 1997, 28:373-377.
66. Gunawardena S., Her L.S., Brusch R.G., Laymon R.A., Niesman I.R., Gordesky-Gold B., Sintasath L., Bonini N.M., Goldstein L.S. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 2003, 40:25-40.
67. Ha B.H., Kim E.E. Structures of proteases for ubiquitin and ubiquitin-like modifiers. BMB Rep. 2008, 41:435-443.
68. Haacke A., Broadley S.A., Boteva R., Tzvetkov N., Hartl F.U., Breuer P. Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3. Hum. Mol. Genet. 2006, 15:555-568.
69. Haacke A., Hartl F.U., Breuer P. Calpain inhibition is sufficient to suppress aggregation of polyglutamine-expanded ataxin-3. J. Biol. Chem. 2007, 282:18851-18856.
70. Harris G.M., Dodelzon K., Gong L., Gonzalez-Alegre P., Paulson H.L. Splice isoforms of the polyglutamine disease protein ataxin-3 exhibit similar enzymatic yet different aggregation properties. PLoS One 2010, 5:e13695.
71. Higashiyama H., Hirose F., Yamaguchi M., Inoue Y.H., Fujikake N., Matsukage A., Kakizuka A. Identification of ter94 Drosophila VCP, as a modulator of polyglutamine-induced neurodegeneration. Cell Death Differ. 2002, 9:264-273.
72. Hirabayashi M., Inoue K., Tanaka K., Nakadate K., Ohsawa Y., Kamei Y., Popiel A.H., Sinohara A., Iwamatsu A., Kimura Y., Uchiyama Y., Hori S., Kakizuka A. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Cell Death Differ. 2001, 8:977-984.
73. Hubener J., Riess O. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models. Neurobiol. Dis. 2010, 38:116-124.
74. Ichikawa Y., Goto J., Hattori M., Toyoda A., Ishii K., Jeong S.Y., Hashida H., Masuda N., Ogata K., Kasai F., Hirai M., Maciel P., Rouleau G.A., Sakaki Y., Kanazawa I. The genomic structure and expression of MJD, the Machado-Joseph disease gene. J. Hum. Genet. 2001, 46:413-422.
75. Ikeda H., Yamaguchi M., Sugai S., Aze Y., Narumiya S., Kakizuka A. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat. Genet. 1996, 13:196-202.
76. Ito Y., Tanaka F., Yamamoto M., Doyu M., Nagamatsu M., Riku S., Mitsuma T., Sobue G. Somatic mosaicism of the expanded CAG trinucleotide repeat in mRNAs for the responsible gene of Machado-Joseph disease (MJD), dentatorubral-pallidoluysian atrophy (DRPLA), and spinal and bulbar muscular atrophy (SBMA). Neurochem. Res. 1998, 23:25-32.
77. Jana N.R., Dikshit P., Goswami A., Kotliarova S., Murata S., Tanaka K., Nukina N. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J. Biol. Chem. 2005, 280:11635-11640.
78. Jana N.R., Nukina N. Misfolding promotes the ubiquitination of polyglutamine-expanded ataxin-3, the defective gene product in SCA3/MJD. Neurotox. Res. 2004, 6:523-533.
79. Jung J., Xu K., Lessing D., Bonini N.M. Preventing ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3. Hum. Mol. Genet. 2009, 18:4843-4852.
80. Kanda T., Isozaki E., Kato S., Tanabe H., Oda M. Type III Machado-Joseph disease in a Japanese family: a clinicopathological study with special reference to the peripheral nervous system. Clin. Neuropathol. 1989, 8:134-141.
81. Kawaguchi Y., Okamoto T., Taniwaki M., Aizawa M., Inoue M., Katayama S., Kawakami H., Nakamura S., Nishimura M., Akiguchi I., et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat. Genet. 1994, 8:221-228.
82. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
83. Kayed R., Sokolov Y., Edmonds B., McIntire T.M., Milton S.C., Hall J.E., Glabe C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 2004, 279:46363-46366.
84. Kuhlbrodt K., Janiesch P.C., Kevei E., Segref A., Barikbin R., Hoppe T. The Machado-Joseph disease deubiquitylase ATX-3 couples longevity and proteostasis. Nat. Cell Biol. 2011, 13:273-281.
85. La Spada A.R., Taylor J.P. Polyglutamines placed into context. Neuron 2003, 38:681-684.
86. Lang A.E., Rogaeva E.A., Tsuda T., Hutterer J., St George-Hyslop P. Homozygous inheritance of the Machado-Joseph disease gene. Ann. Neurol. 1994, 36:443-447.
87. Li F., Macfarlan T., Pittman R.N., Chakravarti D. Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities. J. Biol. Chem. 2002, 277:45004-45012.
88. Li L.B., Yu Z., Teng X., Bonini N.M. RNA toxicity is a component of ataxin-3 degeneration in Drosophila. Nature 2008, 453:1107-1111.
89. Macedo-Ribeiro S., Cortes L., Maciel P., Carvalho A.L. Nucleocytoplasmic shuttling activity of ataxin-3. PLoS One 2009, 4:e5834.
90. Maciel P., Costa M.C., Ferro A., Rousseau M., Santos C.S., Gaspar C., Barros J., Rouleau G.A., Coutinho P., Sequeiros J. Improvement in the molecular diagnosis of Machado-Joseph disease. Arch. Neurol. 2001, 58:1821-1827.
91. Maciel P., Gaspar C., DeStefano A.L., Silveira I., Coutinho P., Radvany J., Dawson D.M., Sudarsky L., Guimaraes J., Loureiro J.E., et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am. J. Hum. Genet. 1995, 57:54-61.
92. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
93. Mao Y., Senic-Matuglia F., Di Fiore P.P., Polo S., Hodsdon M.E., De Camilli P. Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:12700-12705.
94. Markossian K.A., Kurganov B.I. Protein folding, misfolding, and aggregation. Formation of inclusion bodies and aggresomes. Biochemistry (Mosc.) 2004, 69:971-984.
95. Masino L., Musi V., Menon R.P., Fusi P., Kelly G., Frenkiel T.A., Trottier Y., Pastore A. Domain architecture of the polyglutamine protein ataxin-3: a globular domain followed by a flexible tail. FEBS Lett. 2003, 549:21-25.
96. Masino L., Nicastro G., Calder L., Vendruscolo M.A.P. Functional interactions as a survival strategy against abnormal aggregation. FASEB J. 2011, 25:45-54.
97. Masino L., Nicastro G., Menon R.P., Dal Piaz F., Calder L., Pastore A. Characterization of the structure and the amyloidogenic properties of the Josephin domain of the polyglutamine-containing protein ataxin-3. J. Mol. Biol. 2004, 344:1021-1035.
98. Matsumoto M., Yada M., Hatakeyama S., Ishimoto H., Tanimura T., Tsuji S., Kakizuka A., Kitagawa M., Nakayama K.I. Molecular clearance of ataxin-3 is regulated by a mammalian E4. EMBO J. 2004, 23:659-669.
99. Mayer U. Integrins: redundant or important players in skeletal muscle?. J. Biol. Chem. 2003, 278:14587-14590.
100. Mazzucchelli S., De Palma A., Riva M., D'Urzo A., Pozzi C., Pastori V., Comelli F., Fusi P., Vanoni M., Tortora P., Mauri P., Regonesi M.E. Proteomic and biochemical analyses unveil tight interaction of ataxin-3 with tubulin. Int. J. Biochem. Cell Biol. 2009, 41:2485-2492.
101. McCampbell A., Taylor J.P., Taye A.A., Robitschek J., Li M., Walcott J., Merry D., Chai Y., Paulson H., Sobue G., Fischbeck K.H. CREB-binding protein sequestration by expanded polyglutamine. Hum. Mol. Genet. 2000, 9:2197-2202.
102. Menzies F.M., Hourez R., Imarisio S., Raspe M., Sadiq O., Chandraratna D., O'Kane C., Rock K.L., Reits E., Goldberg A.L., Rubinsztein D.C. Puromycin-sensitive aminopeptidase protects against aggregation-prone proteins via autophagy. Hum. Mol. Genet. 2010, 19:4573-4586.
103. Menzies F.M., Huebener J., Renna M., Bonin M., Riess O., Rubinsztein D.C. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain 2010, 133:93-104.
104. Miller S.L., Malotky E., O'Bryan J.P. Analysis of the role of ubiquitin-interacting motifs in ubiquitin binding and ubiquitylation. J. Biol. Chem. 2004, 279:33528-33537.
105. Miller V.M., Nelson R.F., Gouvion C.M., Williams A., Rodriguez-Lebron E., Harper S.Q., Davidson B.L., Rebagliati M.R., Paulson H.L. CHIP suppresses polyglutamine aggregation and toxicity in vitro and in vivo. J. Neurosci. 2005, 25:9152-9161.
106. Miller V.M., Xia H., Marrs G.L., Gouvion C.M., Lee G., Davidson B.L., Paulson H.L. Allele-specific silencing of dominant disease genes. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:7195-7200.
107. Mori F., Nishie M., Piao Y.S., Kito K., Kamitani T., Takahashi H., Wakabayashi K. Accumulation of NEDD8 in neuronal and glial inclusions of neurodegenerative disorders. Neuropathol. Appl. Neurobiol. 2005, 31:53-61.
108. Muchowski P.J., Schaffar G., Sittler A., Wanker E.E., Hayer-Hartl M.K., Hartl F.U. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:7841-7846.
109. Muchowski P.J., Wacker J.L. Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 2005, 6:11-22.
110. Mueller T., Breuer P., Schmitt I., Walter J., Evert B.O., Wullner U. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3. Hum. Mol. Genet. 2009, 18:3334-3343.
111. Nagai Y., Inui T., Popiel H.A., Fujikake N., Hasegawa K., Urade Y., Goto Y., Naiki H., Toda T. A toxic monomeric conformer of the polyglutamine protein. Nat. Struct. Mol. Biol. 2007, 14:332-340.
112. Nicastro G., Masino L., Esposito V., Menon R.P., De Simone A., Fraternali F., Pastore A. Josephin domain of ataxin-3 contains two distinct ubiquitin-binding sites. Biopolymers 2009, 91:1203-1214.
113. Nicastro G., Menon R.P., Masino L., Knowles P.P., McDonald N.Q., Pastore A. The solution structure of the Josephin domain of ataxin-3: structural determinants for molecular recognition. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:10493-10498.
114. Nicastro G., Todi S.V., Karaca E., Bonvin A.M., Paulson H.L., Pastore A. Understanding the role of the Josephin domain in the PolyUb binding and cleavage properties of ataxin-3. PLoS One 2010, 5:e12430.
115. Nijman S.M., Luna-Vargas M.P., Velds A., Brummelkamp T.R., Dirac A.M., Sixma T.K., Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005, 123:773-786.
116. Ordway J.M., Cearley J.A., Detloff P.J. CAG-polyglutamine-repeat mutations: independence from gene context. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 1999, 354:1083-1088.
117. Paulson H.L., Bonini N.M., Roth K.A. Polyglutamine disease and neuronal cell death. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:12957-12958.
118. Paulson H.L., Das S.S., Crino P.B., Perez M.K., Patel S.C., Gotsdiner D., Fischbeck K.H., Pittman R.N. Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann. Neurol. 1997, 41:453-462.
119. Paulson H.L., Perez M.K., Trottier Y., Trojanowski J.Q., Subramony S.H., Das S.S., Vig P., Mandel J.L., Fischbeck K.H., Pittman R.N. Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 1997, 19:333-344.
120. Pennuto M., Palazzolo I., Poletti A. Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. Hum. Mol. Genet. 2009, 18:R40-R47.
121. Perez M.K., Paulson H.L., Pendse S.J., Saionz S.J., Bonini N.M., Pittman R.N. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. J. Cell Biol. 1998, 143:1457-1470.
122. Perez M.K., Paulson H.L., Pittman R.N. Ataxin-3 with an altered conformation that exposes the polyglutamine domain is associated with the nuclear matrix. Hum. Mol. Genet. 1999, 8:2377-2385.
123. Pountney D.L., Huang Y., Burns R.J., Haan E., Thompson P.D., Blumbergs P.C., Gai W.P. SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Exp. Neurol. 2003, 184:436-446.
124. Pozzi C., Valtorta M., Tedeschi G., Galbusera E., Pastori V., Bigi A., Nonnis S., Grassi E., Fusi P. Study of subcellular localization and proteolysis of ataxin-3. Neurobiol. Dis. 2008, 30:190-200.
125. Ranum L.P., Lundgren J.K., Schut L.J., Ahrens M.J., Perlman S., Aita J., Bird T.D., Gomez C., Orr H.T. Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia. Am. J. Hum. Genet. 1995, 57:603-608.
126. Reina C.P., Zhong X., Pittman R.N. Proteotoxic stress increases nuclear localization of ataxin-3. Hum. Mol. Genet. 2010, 19:235-249.
127. Reyes-Turcu F.E., Ventii K.H., Wilkinson K.D. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu. Rev. Biochem 2009, 78:363-397.
128. Reyes-Turcu F.E., Wilkinson K.D. Polyubiquitin binding and disassembly by deubiquitinating enzymes. Chem. Rev. 2009, 109:1495-1508.
129. Riess O., Rüb U., Pastore A., Bauer P., Schöls L. SCA3: neurological features, pathogenesis and animal models. Cerebellum 2008, 7(2):125-137.
130. Robertson A.L., Bottomley S.P. Towards the treatment of polyglutamine diseases: the modulatory role of protein context. Curr. Med. Chem. 2010, 17:3058-3068.
131. Rodrigues A.J., Coppola G., Santos C., Costa Mdo C., Ailion M., Sequeiros J., Geschwind D.H., Maciel P. Functional genomics and biochemical characterization of the C. elegans orthologue of the Machado-Joseph disease protein ataxin-3. FASEB J. 2007, 21:1126-1136.
132. Rodrigues A.J., do Carmo Costa M., Silva T.L., Ferreira D., Bajanca F., Logarinho E., Maciel P. Absence of ataxin-3 leads to cytoskeletal disorganization and increased cell death. Biochim. Biophys. Acta 2010, 1803:1154-1163.
133. Rosenberg R.N. Machado-Joseph disease: an autosomal dominant motor system degeneration. Mov. Disord. 1992, 7:193-203.
134. Ross C.A., Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10(Suppl):S10-S17.
135. Rub U., Brunt E.R., Deller T. New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr. Opin. Neurol. 2008, 21:111-116.
136. Saunders H.M., Bottomley S.P. Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins. Protein Eng. Des. Sel. 2009, 22:447-451.
137. Schaffar G., Breuer P., Boteva R., Behrends C., Tzvetkov N., Strippel N., Sakahira H., Siegers K., Hayer-Hartl M., Hartl F.U. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. Mol. Cell 2004, 15:95-105.
138. Scheel H., Tomiuk S., Hofmann K. Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. Hum. Mol. Genet. 2003, 12:2845-2852.
139. Schmidt T., Landwehrmeyer G.B., Schmitt I., Trottier Y., Auburger G., Laccone F., Klockgether T., Volpel M., Epplen J.T., Schols L., Riess O. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol. 1998, 8:669-679.
140. Schmidt T., Lindenberg K.S., Krebs A., Schols L., Laccone F., Herms J., Rechsteiner M., Riess O., Landwehrmeyer G.B. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions. Ann. Neurol. 2002, 51:302-310.
141. Schmitt I., Linden M., Khazneh H., Evert B.O., Breuer P., Klockgether T., Wuellner U. Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem. Biophys. Res. Commun. 2007, 362:734-739.
142. Schols L., Bauer P., Schmidt T., Schulte T., Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 2004, 3:291-304.
143. Seidel K., den Dunnen W.F., Schultz C., Paulson H., Frank S., de Vos R.A., Brunt E.R., Deller T., Kampinga H.H., Rub U. Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol. 2010, 120:449-460.
144. Seilhean D., Takahashi J., El Hachimi K.H., Fujigasaki H., Lebre A.S., Biancalana V., Durr A., Salachas F., Hogenhuis J., de The H., Hauw J.J., Meininger V., Brice A., Duyckaerts C. Amyotrophic lateral sclerosis with neuronal intranuclear protein inclusions. Acta Neuropathol. 2004, 108:81-87.
145. Shao J., Diamond M.I. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum. Mol. Genet. 2007, 16:R115-R123. (Spec No. 2).
146. Shimizu H., Yamada M., Toyoshima Y., Ikeuchi T., Onodera O., Takahashi H. Involvement of Onuf's nucleus in Machado-Joseph disease: a morphometric and immunohistochemical study. Acta Neuropathol. 2010, 120:439-448.
147. Silva-Fernandes A., Costa Mdo C., Duarte-Silva S., Oliveira P., Botelho C.M., Martins L., Mariz J.A., Ferreira T., Ribeiro F., Correia-Neves M., Costa C., Maciel P. Motor uncoordination and neuropathology in a transgenic mouse model of Machado-Joseph disease lacking intranuclear inclusions and ataxin-3 cleavage products. Neurobiol. Dis. 2010, 40:163-176.
148. Slow E.J., Graham R.K., Osmand A.P., Devon R.S., Lu G., Deng Y., Pearson J., Vaid K., Bissada N., Wetzel R., Leavitt B.R., Hayden M.R. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11402-11407.
149. Song A.X., Zhou C.J., Peng Y., Gao X.C., Zhou Z.R., Fu Q.S., Hong J., Lin D.H., Hu H.Y. Structural transformation of the tandem ubiquitin-interacting motifs in ataxin-3 and their cooperative interactions with ubiquitin chains. PLoS One 2010, 5:e13202.
150. Soong B., Cheng C., Liu R., Shan D. Machado-Joseph disease: clinical, molecular, and metabolic characterization in Chinese kindreds. Ann. Neurol. 1997, 41:446-452.
151. Steffan J.S., Agrawal N., Pallos J., Rockabrand E., Trotman L.C., Slepko N., Illes K., Lukacsovich T., Zhu Y.Z., Cattaneo E., Pandolfi P.P., Thompson L.M., Marsh J.L. SUMO modification of Huntingtin and Huntington's disease pathology. Science 2004, 304:100-104.
152. Sudarsky L., Coutinho P. Machado-Joseph disease. Clin. Neurosci. 1995, 3:17-22.
153. Sugiura A., Yonashiro R., Fukuda T., Matsushita N., Nagashima S., Inatome R., Yanagi S. A mitochondrial ubiquitin ligase MITOL controls cell toxicity of polyglutamine-expanded protein. Mitochondrion 2010, 11:139-146.
154. Tait D., Riccio M., Sittler A., Scherzinger E., Santi S., Ognibene A., Maraldi N.M., Lehrach H., Wanker E.E. Ataxin-3 is transported into the nucleus and associates with the nuclear matrix. Hum. Mol. Genet. 1998, 7:991-997.
155. Takahashi J., Tanaka J., Arai K., Funata N., Hattori T., Fukuda T., Fujigasaki H., Uchihara T. Recruitment of nonexpanded polyglutamine proteins to intranuclear aggregates in neuronal intranuclear hyaline inclusion disease. J. Neuropathol. Exp. Neurol. 2001, 60:369-376.
156. Takiyama Y., Nishizawa M., Tanaka H., Kawashima S., Sakamoto H., Karube Y., Shimazaki H., Soutome M., Endo K., Ohta S., et al. The gene for Machado-Joseph disease maps to human chromosome 14q. Nat. Genet. 1993, 4:300-304.
157. Tanaka M., Morishima I., Akagi T., Hashikawa T., Nukina N. Intra- and intermolecular beta-pleated sheet formation in glutamine-repeat inserted myoglobin as a model for polyglutamine diseases. J. Biol. Chem. 2001, 276:45470-45475.
158. Tao R.S., Fei E.K., Ying Z., Wang H.F., Wang G.H. Casein kinase 2 interacts with and phosphorylates ataxin-3. Neurosci. Bull. 2008, 24:271-277.
159. Tarlac V., Storey E. Role of proteolysis in polyglutamine disorders. J. Neurosci. Res. 2003, 74:406-416.
160. Terashima T., Kawai H., Fujitani M., Maeda K., Yasuda H. SUMO-1 co-localized with mutant atrophin-1 with expanded polyglutamines accelerates intranuclear aggregation and cell death. Neuroreport 2002, 13:2359-2364.
161. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., Hansen L.A., Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 1991, 30:572-580.
162. Todi S.V., Laco M.N., Winborn B.J., Travis S.M., Wen H.M., Paulson H.L. Cellular turnover of the polyglutamine disease protein ataxin-3 is regulated by its catalytic activity. J. Biol. Chem. 2007, 282:29348-29358.
163. Todi S.V., Scaglione K.M., Blount J.R., Basrur V., Conlon K.P., Pastore A., Elenitoba-Johnson K., Paulson H.L. Activity and cellular functions of the deubiquitinating enzyme and polyglutamine disease protein ataxin-3 are regulated by ubiquitination at lysine 117. J. Biol. Chem. 2010, 285:39303-39313.
164. Todi S.V., Winborn B.J., Scaglione K.M., Blount J.R., Travis S.M., Paulson H.L. Ubiquitination directly enhances activity of the deubiquitinating enzyme ataxin-3. EMBO J. 2009, 28:372-382.
165. Trottier Y., Cancel G., An-Gourfinkel I., Lutz Y., Weber C., Brice A., Hirsch E., Mandel J.L. Heterogeneous intracellular localization and expression of ataxin-3. Neurobiol. Dis. 1998, 5:335-347.
166. Tsai Y.C., Fishman P.S., Thakor N.V., Oyler G.A. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem. 2003, 278:22044-22055.
167. Tzvetkov N., Breuer P. Josephin domain-containing proteins from a variety of species are active de-ubiquitination enzymes. Biol. Chem. 2007, 388:973-978.
168. Uchihara T., Fujigasaki H., Koyano S., Nakamura A., Yagishita S., Iwabuchi K. Non-expanded polyglutamine proteins in intranuclear inclusions of hereditary ataxias-triple-labeling immunofluorescence study. Acta Neuropathol. 2001, 102:149-152.
169. Ueda H., Goto J., Hashida H., Lin X., Oyanagi K., Kawano H., Zoghbi H.Y., Kanazawa I., Okazawa H. Enhanced SUMOylation in polyglutamine diseases. Biochem. Biophys. Res. Commun. 2002, 293:307-313.
170. Uversky V.N. Mysterious oligomerization of the amyloidogenic proteins. FEBS J. 2010, 277:2940-2953.
171. Wada K., Kamitani T. UnpEL/Usp4 is ubiquitinated by Ro52 and deubiquitinated by itself. Biochem. Biophys. Res. Commun. 2006, 342:253-258.
172. Wang G., Ide K., Nukina N., Goto J., Ichikawa Y., Uchida K., Sakamoto T., Kanazawa I. Machado-Joseph disease gene product identified in lymphocytes and brain. Biochem. Biophys. Res. Commun. 1997, 233:476-479.
173. Wang G., Sawai N., Kotliarova S., Kanazawa I., Nukina N. Ataxin-3, the MJD1 gene product, interacts with the two human homologs of yeast DNA repair protein RAD23, HHR23A and HHR23B. Hum. Mol. Genet. 2000, 9:1795-1803.
174. Wang Q., Li L., Ye Y. Regulation of retrotranslocation by p97-associated deubiquitinating enzyme ataxin-3. J. Cell Biol. 2006, 174:963-971.
175. Wang Q., Li L., Ye Y. Inhibition of p97-dependent protein degradation by Eeyarestatin I. J. Biol. Chem. 2008, 283:7445-7454.
176. Wang Q., Song C., Li C.C. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. J. Struct. Biol. 2004, 146:44-57.
177. Warrick J.M., Chan H.Y., Gray-Board G.L., Chai Y., Paulson H.L., Bonini N.M. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat. Genet. 1999, 23:425-428.
178. Warrick J.M., Morabito L.M., Bilen J., Gordesky-Gold B., Faust L.Z., Paulson H.L., Bonini N.M. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol. Cell 2005, 18:37-48.
179. Warrick J.M., Paulson H.L., Gray-Board G.L., Bui Q.T., Fischbeck K.H., Pittman R.N., Bonini N.M. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998, 93:939-949.
180. Weinberg M.S., Wood M.J. Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics. Hum. Mol. Genet. 2009, 18:R27-R39.
181. Weissman A.M. Themes and variations on ubiquitylation. Nat. Rev. Mol. Cell Biol. 2001, 2:169-178.
182. Wellington C.L., Ellerby L.M., Hackam A.S., Margolis R.L., Trifiro M.A., Singaraja R., McCutcheon K., Salvesen G.S., Propp S.S., Bromm M., Rowland K.J., Zhang T., Rasper D., Roy S., Thornberry N., Pinsky L., Kakizuka A., Ross C.A., Nicholson D.W., Bredesen D.E., Hayden M.R. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 1998, 273:9158-9167.
183. Wen F.C., Li Y.H., Tsai H.F., Lin C.H., Li C., Liu C.S., Lii C.K., Nukina N., Hsieh M. Down-regulation of heat shock protein 27 in neuronal cells and non-neuronal cells expressing mutant ataxin-3. FEBS Lett. 2003, 546:307-314.
184. Williams A.J., Paulson H.L. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 2008, 31:521-528.
185. Winborn B.J., Travis S.M., Todi S.V., Scaglione K.M., Xu P., Williams A.J., Cohen R.E., Peng J., Paulson H.L. The deubiquitinating enzyme ataxin-3, a polyglutamine disease protein, edits Lys63 linkages in mixed linkage ubiquitin chains. J. Biol. Chem. 2008, 283:26436-26443.
186. Wullner U., Reimold M., Abele M., Burk K., Minnerop M., Dohmen B.M., Machulla H.J., Bares R., Klockgether T. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch. Neurol. 2005, 62:1280-1285.
187. Yamada M., Hayashi S., Tsuji S., Takahashi H. Involvement of the cerebral cortex and autonomic ganglia in Machado-Joseph disease. Acta Neuropathol. 2001, 101:140-144.
188. Yen T.C., Lu C.S., Tzen K.Y., Wey S.P., Chou Y.H., Weng Y.H., Kao P.F., Ting G. Decreased dopamine transporter binding in Machado-Joseph disease. J. Nucl. Med. 2000, 41:994-998.
189. Ying Z., Wang H., Fan H., Zhu X., Zhou J., Fei E., Wang G. Gp78, an ER associated E3, promotes SOD1 and ataxin-3 degradation. Hum. Mol. Genet. 2009, 18:4268-4281.
190. Yoshizawa T., Yamagishi Y., Koseki N., Goto J., Yoshida H., Shibasaki F., Shoji S., Kanazawa I. Cell cycle arrest enhances the in vitro cellular toxicity of the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch. Hum. Mol. Genet. 2000, 9:69-78.
191. Zander C., Takahashi J., El Hachimi K.H., Fujigasaki H., Albanese V., Lebre A.S., Stevanin G., Duyckaerts C., Brice A. Similarities between spinocerebellar ataxia type 7 (SCA7) cell models and human brain: proteins recruited in inclusions and activation of caspase-3. Hum. Mol. Genet. 2001, 10:2569-2579.
192. Zhong X., Pittman R.N. Ataxin-3 binds VCP/p97 and regulates retrotranslocation of ERAD substrates. Hum. Mol. Genet. 2006, 15:2409-2420.
193. Zoghbi H.Y., Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 2000, 23:217-247.